Introduction
secretion. The ability to add or delete specific genes in animals However, the identification of a mutation in a canhas provided a powerful experimental system to didate gene is not always sufficient to demonstrate study pathophysiological aspects of gene expression a causal relationship with the disease. A causal and function. Recent advances in molecular genetics relationship can be confirmed by introducing preand transgenic technology have provided an opportdefined changes into the genome of experimental unity to explore the consequences of a 'gain of funcanimals, which can then lead to the predicted tion' or 'loss of function' approach for the study of phenotype. 2 Such genetic changes have resulted in physiological systems in vivo.
1 Genes thought to be the generation of transgenic rat models in which involved in hypertension have been a central target many important genes concerning hypertension are for transgenic studies. Careful assessment of the manipulated. The study of essential hypertension is hypertensive phenotype in the genetically maniputhought to be more complex than single gene alterlated animal plays an equally important part in ations, since multiple genes are thought to be defining the function of the given candidate gene.
involved and variants at mani loci, some of which The choice of the transgene gene thought to be may be common, appear to contribute to the blood related to a hypertensive phenotype presents a partipressure (BP) variation in humans. 11 This vastly cular challenge because hypertension is often multicomplicates genetic strategies, since different comfactorial in origin, resulting from the interaction of binations of genetic factors may result in hypertengenetic and environmental factors. For many forms sion in different individuals, even within the same of hypertension the relative importance of genetic pedigree. 12 Transgenic models can help test some of factors is poorly defined, but for others genetic facthe candidate genes thought to be involved in hypertors clearly play a central role. 2 In humans, one of tension. The renin-angiotensin system (RAS) is the best defined monogenetic hypertensive diseases viewed as an important system in the pathogenesis is the glucocorticoid remediable hypertension of hypertension. The effectiveness of angiotensinwhich is caused by a chimeric 11␤-hydroxylase/ converting enzyme (ACE)-inhibitors exemplified the aldosterone synthase gene.
3 This is an autosomal important role of the RAS in hypertension. Specifidominant disorder, characterised by variable hypercally, alterations in the RAS may contribute to the aldosteronism 4,5 and by high levels of the abnormal complex appearance of hypertension. To further disadrenal steroids 18-oxocortisol and 18-hydroxysect a role of the RAS and the endothelin system in cortisol, 6, 7 which are all under control of adrenocorthypertension, rats overexpressing the RAS compoicotropic hormone and suppressible by glucocortnents or components of the endothelin system icoids.
8 Another example for a monogenetic hyperwere developed. tensive disease is Liddle's syndrome which is caused by a mutation in the ␤-subunit of the epiRats expressing components of the RAS thelial sodium channel, 9 leading to pseudoaldostronism, with early onset severe hypertenThe Ren-2 transgenic rat, TGR(mREN2)27 sion 10 and hypokalaemia. The hypokalaemia can be The Ren-2 transgenic rat is a transgenic model an indication that the hypertension might be due to which contains the murine Ren-2 gene. RAS is a excessive sodium reabsorption in the distal nephcentral regulatory system in BP control and volume ron, where sodium reabsorption via the mineralohomeostasis and has been implicated in the pathocorticoid-regulated, amiloride-sensitive, epithelial physiology of hypertension. Several mouse strains contain two renin genes (Ren-1 and Ren-2). The TRG (mRen2)27 has been designed to show the physiological and pathophysiological relevance of the Ren- of human renin to physiologic and pathophysiologThese homozygous animals die from cardiovascular ical stimuli. Results indicated that human renin did complications such as heart and kidney failure as not interact with the endogenous rat angiotensinwell as stroke, if not treated with antihypertensive ogen, leaving the plasma ANG I and ANG II levels drugs.
14 This transgenic rat has originally been unchanged. A high level of expression of human described as a model with suppressed plasma RAS renin was found in the kidney and low expression but elevated renin expression in extrarenal tissues, 15 levels were present in lung, thymus and gastrointesfor example in the vasculature, 16 adrenals 14,17 and tinal tract. Systolic BP (SBP) in the TGR(hREN) rat heart. 18 This suggests that the activated extrarenal was normal. Confirming the species specificity of RAS might be responsible for the hypertensive the human renin. This is probably due to the fact phenotype. Furthermore the REN-2 gene increases that the human renin does not interact with the rat local formation of ANG II, which then acts on target angiotensinogen and therefore does not elevate tissues in a paracrine or autocrine manner. 15 This ANG II. 21 local ANG II formation may be a key factor for the changes in cardiovascular morphology that appear to be partially independent from BP. Even so, is the The human angiotensinogen transgenic rat, endothelial dysfunction, which is more severe in the TGR(hAOGEN) Ren-2 rat compared to the spontaneous hypertensive
The TGR(hAOGEN) rat is a transgenic model which rat, possibly due to this elevated local ANG II. 18 That harbours the human angiotensinogen gene. The these pathophysiological changes are due to ANG II plasma levels of human angiotensinogen were is emphasised by the treatment with antihypertenextremely elevated in the TGR(hAOGEN) compared sive drugs. They show that the transgenic rat to undetectable levels in transgenic-negative rats. responded with improvement of endothelial func-
The parameters of the rat RAS, prorenin, renin, tion 19 and cardiovascular morphological changes 20 angiotensinogen, ANG II and converting enzyme to ACE-inhibitors or ANG II receptor antagonists.
remained unchanged in all lines, indicating that there is no reaction between human angiotensinogen Merits of the model: The TGR(REN2(27) rat demand rat renin, even at very high plasma levels. High onstrates the biological relevance of renin-2 in vivo. levels of transgene expression were found in the Furthermore it represents the first rat model of liver, kidney, brain, lung, heart and gastrointestinal hypertension with a monogenetic defect which demtract. Variable expression was found in the salivary onstrates in a very intriguing way that the RAS can glands, spleen and muscle. The SBP was not elevbe causally involved in the hypertensive process, ated under basic conditions, but human renin even in the absence of elevated circulating renin. infusion elicited a hypertensive response which They provide a sophisticated approach to analyse could be blocked by a specific human renin inhibiphenotypic consequences of defined genetic altertor (Ro 42-5892). In a following experiment rat renin ation in an in vivo system and provide information was infused and though BP increased, this effect about the role of the RAS in end-organ damage.
could not be blocked by the human renin inhibitor. 20 This demonstrates that human angiotensinLimitations of the model: Although the ogen is not species specific, because it can be con-TGR(Ren2)27 rat provide a large amount of inforverted by rat renin, but instead human renin is, mation on the role of the RAS in cardiovascular disbecause this does not convert rat angiotensinogen. ease, they cannot be considered as a genuine model
On the other hand this model is an excellent model of human hypertension, which is polygenic in for the development of renin specific drugs. 21 nature.
Biological implications: This transgenic model
The human renin/angiotensinogen transgenic rat, probably represents one of the most convincing TGR(hREN*hAOGEN) pieces of evidence for a physiological significance of tissue-resident RAS and suggests that they may
The TGR(hREN*hAOGEN) rat is a transgenic model which harbours the entire human angiotensinogen be involved in the pathogenesis of specific forms of hypertension associated with normal or low plasma and the entire human renin gene. Heterozygous human renin transgenic rats were crossbred with renin. Enhancing our knowledge regarding the transgenic rat may ultimately lead to a better understandheterozygous rats transgenic for the human angiotensinogen gene. From their offspring, rats haring of the mechanisms by which the RAS contributes to the pathogenesis of hypertension, providing bouring the human angiotensinogen and renin gene could be obtained. Like the TGR(hREN) rat and the the basis for future studies in humans.
TGR(HAOGEN) rat these rats also did not develop possible cardiac changes induced by ACE overexpression in this model are in progress. spontaneous hypertension. Investigations that manipulate the RAS, such as alterations in sodium homeostasis, are necessary to elucidate the interacMerits of the model: The ACE transgenic rat model tion of human transgenes and its effect on BP develallows us a selective investigation of cardiac ACE in opment in this model. 21 cardiovascular pathophysiology. In another experiment, the homozygous human renin transgenic rat was crossbred with the homozygous human angiotensinogen rat. These rats Rats expressing components of the developed severe hypertension with systolic presendothelin system sure of 200 mm Hg and died without treatment in 8 weeks. The rats featured severe cardiac hypertrophy,
The human endothelin transgenic rat, TGR(hETwith increased cross-section of cardiomyocytes but 2)37 little myocardial fibrosis. The kidneys showed atrophic tubules, thickened vessel walls, and
The TGR(hET-2)37 rat is a transgenic model which harbours the human endothelin-2 (ET-2) gene. The increased interstitium. 22 These two models show that the hypertension seen here could be related to reason to construct this model was because endothelins are thought to play an important role in carthe further increased levels of human renin and human angiotensinogen in the homozygous, because diovasculare regulation. ET-1 was the first of the isopeptides to be characterised in the supernatant of the heterozygous crossbreds did not show hypertension.
cultured vascular endothelial cells. 24 In addition to their vasoactive properties, endothelins have been shown to elicit a wide variety of biological activities Merits of the model: The renin (TGR(hREN)) transin non-vascular tissues, including the kidney. 25 genic rat and also the angiotensinogen (TGR Besides this ET-1 is reported to be a mitogen in sev-(hAOGEN)) and renin/angiotensinogen (TGR(hREN* eral cultured cell lines including vascular smooth hAOGEN)) transgenic rats, allow studies into the muscle cells. [26] [27] [28] regulation of human genes in non-primate animal Analysis of transgenic animals by Northern blotmodels. The most important finding in these experiting revealed a marked overexpression of the transments was the fact that the human renin and angiotgene in several orans such as kidney, lung, gastroensinogen genes were expressed in the newly estabintestinal and brain. By radioimmunoassay (RIA) we lished transgenic rats and that the translation demonstrated a significant increase of human ET-2 products renin and angiotensinogen did not crossreand its precursor, 'big' ET-2, in the plasma of transact enzymatically with the RAS and vice versa. This genic rats compared with non-transgenic littermates. finding illustrates the unique species specificity of Nevertheless, BP and heart weight remained the RAS and allows for human-specific testing of in unchanged. Also RT-PCR for ET A receptor-specific vivo and in vitro enzyme kinetics in these transgenic mRNA failed to reveal a significant difference rats. The fact that this rat had no high ANG II levels between transgenic animals and controls. Concernand no hypertension shows us the importance of ing the expression level of specific ET B receptor ANG II in the RAS system on hypertension.
mRNA, the authors also found no changes by use of competitive RT-PCR between transgenic animals Limitations of the model: The TGR(hREN) rat has and controls. 29 Therefore, the reason why the no hypertension therefore the effect of human renin TGR(hET-2)37 rat is not hypertensive is still on hypertension and end-organ damage cannot be unclear. investigated.
Apparently it is not caused by downregulation or overexpression of endothelin receptors at the mRNA Biological implications: The unique species specilevel. It may be due to counterregulation by other ficity of the renin substrate reaction is advantageous vasoactive systems. Despite normal BP, heterofor developing and testing human specific renin zygous TGR(hET-2)37 rats developed significant inhibitors. Furthermore, the model will also be helpmorphological changes in the kidney compared with ful to overcome the problems and limitations age-matched controls. Transgenic rats had a signifiinherent in human research directed at the developcantly increased amount of periodic acid schiff ment of human-specific drugs to interfere with the (PAS)-positive material within the glomeruli. Using RAS.
the glomerular injury score according to Raij et al 30 the TGR(hET-2)37 transgenic rat had a significantly increased glomerulosclerosis index. 31 Even so uriThe cardiac ACE transgenic rat, TGR(hACE) nary protein concentration and protein excretion significantly increased in 12-month-old heteroThe TGR(hACE) rat is a new transgenic model which harbours the human ACE gene and overexzygous female TGR(hET-2)37 rats compared with corresponding controls. The finding of glomerupresses ACE in the heart. Enzyme activity of ACE was increased nearly 50-fold in the heart, whereas losclerosis and proteinuria, in combination with findings showing elevated endothelin levels in heart it was only slightly elevated in skeletal muscle and not increased in all other tissues tested. The cardiac failure without classic risk factors such as hypertension, makes it possible that the TFR(hET-2)37 rat has overexpression of ACE, did not affect BP in the transgenic rats. 23 Experiments to characterise the endothelial dysfunction. has been expressed even before birth, allowing vari-
